Pfizer says its new crown vaccine is up to 95 percent efficient and plans to apply for emergency use authorization in the United States

PHARP, Nov. 19 (Xinhua) -- U.S. pharmaceutical company Pfizer Inc. and German bioNTech Co., Ltd. announced the latest clinical trial results of their new crown vaccine, saying the vaccine is 95 percent effective and has no serious side effects.
said it plans to apply to the U.S. Food and Drug Administration (FDA) for emergency use authorization "within days."
said that if approved by the U.S. Food and Drug Administration, 50 million doses of the vaccine are expected to be available by the end of 2020 and 1.3 billion doses by the end of 2021.
, director of the Institute for Global Health at Yale University in New York, said that the U.S. B. O'Meyer called on Pfizer to release a more detailed data analysis as soon as possible so that scientists can evaluate vaccine test results more thoroughly.
the results of clinical trials, Pfizer said it was ready to submit its recommended two-month safety data, as well as detailed production records, to the U.S. Food and Drug Administration, according to the report.
said the FDA would review the data and ask an external panel of vaccine experts to evaluate the application, a process that could take weeks.
November 9th local time, Pfizer and BioNTech announced that a candidate vaccine it had developed in partnership was 90 per cent effective.
。